The panelists, Brian Van Tine, MD, PhD; Robin Jones, MD, MRCP; Jonathan Trent, MD, PhD; and Andrew Wagner, MD, PhD; and Shreyaskumar Patel, MD, discuss patient selection and the role of evofosfamide in soft tissue sarcoma.

Jonathan C. Trent, MD, associate director for Clinical Research, director of the Sarcoma Medical Research Program at the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, discusses sequencing trabectedin for patients with soft tissue sarcoma.

Expert panelists William D. Tap, MD; Jonathan C. Trent, MD, PhD; Kristen N. Ganjoo, MD; Victor M. Villalobos, MD, PhD; and Richard F. Riedel, MD, discuss the diagnostic workup for soft tissue sarcoma and the pitfalls related to obtaining an accurate pathologic assessment.

Arun S. Singh, MD, associate professor, Department of Medicine, Division of Hematology/Oncology, University of California, Los Angeles, discusses drug development for the treatment of patients with soft tissue sarcomas.

Saketh Guntupalli, MD, and Victor Villalobos, MD, PhD, highlight some of the more common pitfalls associated with treating soft tissue sarcoma.

Neeta Somaiah, MD, assistant professor, Department of Sarcoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses phase I findings of CMB305 in patients with NY-ESO-1–positive recurrent soft tissue sarcoma.